Clinical trial · Observational
CDK4/6 Inhibitors in Metastatic HR-Positive Breast Cancer
RETROSPECTIVE STUDY OF OUTCOME OF CDK4/6 INHIBITORS IN METASTATIC LUMINAL A AND LUMINAL B BREAST CANCER
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a retrospective review aimed at evaluating the real-world outcomes and clinical efficacy of CDK4/6 inhibitors (such as Palbociclib, Ribociclib, or Abemaciclib) in patients diagnosed with metastatic luminal A and luminal B breast cancer. The study will assess how patients responded to these treatments based on their specific breast cancer subtype (Luminal A vs. Luminal B) by reviewing their medical records.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CDK4/6 inhibitors | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- luminal A subgroup
- description
- patients diagnosed with metastatic breast cancer
- interventionNames
- Drug: CDK4/6 inhibitors
- label
- luminal B subgroup
- description
- patients diagnosed with metastatic breast cancer
- interventionNames
- Drug: CDK4/6 inhibitors
Primary outcomes (3)
- measure
- progression free survival
- timeFrame
- Up to 4 years أو From initiation of CDK4/6 inhibitor therapy to disease progression or death, up to 4 years.
- description
- Progression-free survival is defined as the time from initiation of CDK4/6 inhibitor therapy until documented disease progression or death from any cause.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * patients who are more than 18 years old at time of diagnosis and less than 80 years * metastatic breast cancer luminal A and luminal B of either sex Exclusion Criteria: * patients diagnosed with double malignancy * patients with incomplete medical records * patients with organ failure
References
Publications (0)
Data not yet available